Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
$120.67
-$1.43(-1.02%)
At close: 4:00 PM EST
$120.67
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$68.70 - $153.06
Previous CloseN/A
Volume388.94K
Average Volume (3M)1.84M
Market Cap
$18.44B
Enterprise Value$15.42B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)27.0
Beta1.35
Next Earnings
Feb 05, 2026EPS Estimate
1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding152,800,000
10 Day Avg. Volume1,898,831
30 Day Avg. Volume1,838,607
Financial Highlights & Ratios
PEG Ratio-3.75
Price to Book (P/B)8.95
Price to Sales (P/S)4.86
P/FCF Ratio29.95
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.60
Enterprise Value/Gross Profit5.43
Enterprise Value/Ebitda11.91
Forecast
1Y Price Target
$117.77Price Target Upside-2.40% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)4.69
Revenue Forecast (FY)$4.28B
Bulls Say, Bears Say
Bulls Say
China Market PotentialChina’s Ministry of Commerce lifted export bans on ILMN, allowing the company to regain export eligibility, which supports long-term reengagement in China.
Clinical Consumables GrowthIllumina's clinical consumables revenue continued to accelerate, increasing to +12% y/y as clinical customers transition to the NovaSeq X.
Financial PerformanceILMN stock rose 25% following their 3Q print, reflecting positive investor sentiment.
Bears Say
Market CompetitionThe company's management is underestimating the competitive threat, particularly from competitors like Roche/Axelios, which could impact future performance.
Regulatory ChallengesILMN still remains on the Unreliable Entities List, meaning instrument sales still require government approval.
Structural ChallengesAnalysts maintain an Underperform rating for Illumina, citing structural, competitive, and market challenges.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $153.06 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $18.44B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 05, 2026 which is in 79 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 30, 2025. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.168 by $0.172.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.22.
How many shares outstanding does Illumina have?
Illumina has 152,800,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.34 in its last earnings report, beating expectations of $1.168. Following the earnings report the stock price went up 24.775%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$117.77 (-2.40% Downside)
$117.77 (-2.40% Downside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 81.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.16%
12-Months-Change
Fundamentals
Return on Equity
31.20%
Trailing 12-Months
Asset Growth
2.71%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. (ILMN) is a leading developer and manufacturer of life sciences tools and integrated systems for the analysis of genetic variation and function. Founded in 1998 and headquartered in San Diego, California, Illumina specializes in next-generation sequencing (NGS) technology, genotyping, and microarray solutions. Its products are primarily used in genomics research, clinical applications, and agricultural biotechnology, enabling advancements in personalized medicine, diagnostics, and drug discovery.
ILMN Company Deck
ILMN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical markets and the NovaSeq X transition, with revenue and earnings exceeding expectations. However, challenges in research markets and ongoing issues in China present hurdles. Despite these challenges, the company remains optimistic about its strategic initiatives and future growth.View all ILMN earnings summariesILMN Revenue Breakdown
72.16% Consumables
16.38% Service and other revenue
11.46% Instruments
ILMN Stock 12 Month Forecast
Average Price Target
$117.77
▼(-2.40% Downside)
Technical Analysis
Ownership Overview
2.79% Insiders
29.30% Mutual Funds
32.94% Other Institutional Investors
12.21% Public Companies and Individual Investors